DOES ENDOGENOUS GLYCOSYLATION PREVENT THE USE OF MOUSE MONOCLONAL-ANTIBODIES AS CANCER THERAPEUTICS

Authors
BORREBAECK CAK MALMBORG AC OHLIN M
Citation
Cak. Borrebaeck et al., DOES ENDOGENOUS GLYCOSYLATION PREVENT THE USE OF MOUSE MONOCLONAL-ANTIBODIES AS CANCER THERAPEUTICS, Immunology today, 14(10), 1993, pp. 477-479
Citations number
18
Categorie Soggetti
Immunology
Journal title
Immunology today → ACNP
ISSN journal
01675699
Volume
14
Issue
10
Year of publication
1993
Pages
477 - 479
Database
ISI
SICI code
0167-5699(1993)14:10<477:DEGPTU>2.0.ZU;2-W
Abstract
Monoclonal antibodies have many potential therapeutic benefits. Howeve r, when applied to humans, mouse monoclonal antibodies have several di sadvantages. Here Carl Borrebaeck and colleagues describe a strategy t o overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.